TY - JOUR
T1 - In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infection
AU - Rouse, Mark S.
AU - Steckelberg, James M.
AU - Patel, Robin
N1 - Funding Information:
This study was funded by Johnson & Johnson Pharmaceutical Research and Development, Raritan, NJ.
Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2007/7
Y1 - 2007/7
N2 - We tested the in vitro activity of 4 antimicrobial agents against methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci recovered from patients with endocarditis or bone and joint infection. Ceftobiprole, daptomycin, linezolid, and vancomycin MIC90 values were 1, 1, 2, and 1 μg/mL, respectively. Ceftobiprole, daptomycin, linezolid, and vancomycin MBC90 values were 2, 4, ≥128, and 8 μg/mL, respectively. Ceftobiprole MIC and MBC values were ≤2 μg/mL for all isolates tested, with the exception of one methicillin-resistant coagulase-negative Staphylococcus spp isolate. Vancomycin lacked bactericidal activity (defined as an MBC/MIC ratio of ≥32) against 2 methicillin-resistant Staphylococcus aureus (MRSA) isolates from patients with bone and joint infection; one of these isolates was additionally daptomycin nonsusceptible (daptomycin MIC, 2 μg/mL). There was one additional daptomycin nonsusceptible (daptomycin MIC, 2 μg/mL) isolate (MRSA associated with bone and joint infection). Ceftobiprole demonstrated in vitro bactericidal activity against all MRSA and methicillin-resistant coagulase-negative staphylococci tested.
AB - We tested the in vitro activity of 4 antimicrobial agents against methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci recovered from patients with endocarditis or bone and joint infection. Ceftobiprole, daptomycin, linezolid, and vancomycin MIC90 values were 1, 1, 2, and 1 μg/mL, respectively. Ceftobiprole, daptomycin, linezolid, and vancomycin MBC90 values were 2, 4, ≥128, and 8 μg/mL, respectively. Ceftobiprole MIC and MBC values were ≤2 μg/mL for all isolates tested, with the exception of one methicillin-resistant coagulase-negative Staphylococcus spp isolate. Vancomycin lacked bactericidal activity (defined as an MBC/MIC ratio of ≥32) against 2 methicillin-resistant Staphylococcus aureus (MRSA) isolates from patients with bone and joint infection; one of these isolates was additionally daptomycin nonsusceptible (daptomycin MIC, 2 μg/mL). There was one additional daptomycin nonsusceptible (daptomycin MIC, 2 μg/mL) isolate (MRSA associated with bone and joint infection). Ceftobiprole demonstrated in vitro bactericidal activity against all MRSA and methicillin-resistant coagulase-negative staphylococci tested.
KW - Ceftobiprole
KW - Daptomycin
KW - Linezolid
KW - MRSA
KW - Staphylococcus
KW - Staphylococcus aureus
KW - Vancomycin
UR - http://www.scopus.com/inward/record.url?scp=34347339330&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34347339330&partnerID=8YFLogxK
U2 - 10.1016/j.diagmicrobio.2007.02.010
DO - 10.1016/j.diagmicrobio.2007.02.010
M3 - Article
C2 - 17449212
AN - SCOPUS:34347339330
SN - 0732-8893
VL - 58
SP - 363
EP - 365
JO - Diagnostic Microbiology and Infectious Disease
JF - Diagnostic Microbiology and Infectious Disease
IS - 3
ER -